Amylyx Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
AMLX$30.91+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows used in operating activities: | ||
| Net loss | $(130,196) | $(111,736) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 24,809 | 21,259 |
| Depreciation expense | 174 | 417 |
| Accretion of investment discounts, net | (2,937) | (4,469) |
| Charge for in-process research and development ("IPR&D") milestones | 4,000 | — |
| Other non-cash items | 75 | 264 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,041) | 3,635 |
| Operating lease right-of-use assets | 932 | 1,435 |
| Deposits and other assets | (2) | 24 |
| Accounts payable | 1,284 | 305 |
| Accrued expenses | 4,936 | (5,389) |
| Operating lease liabilities | (1,014) | (1,185) |
| Net cash used in operating activities | (101,980) | (95,440) |
| Cash flows used in investing activities: | ||
| Purchases of property and equipment | (55) | (52) |
| Milestone payments related to IPR&D | (4,000) | — |
| Purchases of marketable securities | (603,985) | (201,377) |
| Proceeds from maturities of marketable securities | 168,840 | 186,000 |
| Net cash used in investing activities | (439,200) | (15,429) |
| Cash flows provided by financing activities: | ||
| Proceeds from financings, net of issuance costs | 544,614 | 256,688 |
| Proceeds from exercise of stock options and RSUs vesting | 20,837 | 3,701 |
| Withholding taxes paid on stock-based awards | (10,597) | (3,152) |
| Net cash provided by financing activities | 554,854 | 257,237 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (218) | 956 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | 13,456 | 147,324 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 227,636 | 78,837 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $241,092 | $226,161 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents: | ||
| Cash and cash equivalents | $240,095 | $225,178 |
| Restricted cash equivalents | 997 | 983 |
| Total cash, cash equivalents and restricted cash equivalents: | $241,092 | $226,161 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.